Any disease not selected as measured (target) lesions should be considered not/non-measurable (non-target) lesions. These sites include any sites not selected as measurable or which do not meet the requirements for measurability but are still considered abnormal including:

Nodes/nodal masses

Extranodal sites of disease

Assessable disease such as bone lesions, effusions, ascites or other truly non-measurable disease that are considered to be manifestations of lymphoma should be followed as non-target sites.

These sites should be assessed collectively for regression, stability and progression as a qualitative measure of response assessment.

Key Offerings

Key Materials

Key Offerings

Key Materials

SHOW MORE

SHOW MORE

Make Non-Target Sites of Disease part of your solution

The correct interpretation and application of published assessment criteria is essential to providing reliable response outcomes that will accurately reflect efficacy and will stand up to scrutiny by regulators. Let PAREXEL guide you to the right response assessment.

Key Topics: 2007 IWG-NHL Assessment Criteria

Products and Services

The correct interpretation and application of published assessment criteria is essential to providing reliable response outcomes that will accurately reflect efficacy and will stand up to scrutiny by regulators. Let PAREXEL guide you to the right response assessment.